Publications – Marika Nestor

Publications in DiVA

Publications in PubMed
 

Selected publications

  1. Lundsten S, Spiegelberg D, Raval N R, Nestor M. The radiosensitizer Onalespib increases complete remission in 177Lu-DOTATATE treated mice bearing neuroendocrine tumor xenografts. Eur J Nucl Med Mol Imaging. 2020, Epub Jan 7.
     
  2. Mortensen A C L, Spiegelberg D, Brown C J, Lane D P, Nestor M. The stapled peptide PM2 stabilizes p53 levels and radiosensitizes wild-type p53 cancer cells. Frontiers in Oncology: Molecular and Cellular Oncology, 2019, 9:92.
     
  3. Mortensen A C L, Morin E, Brown C J, Lane D P, Nestor M. Enhancing therapeutic effects of radio-immunotherapy using the novel stapled MDM2/X-p53 antagonist PM2. Eur J Nucl Med Mol Imaging Res. 2019, In press.
     
  4. Lundsten S, Spiegelberg D, Stenerlöw B, Nestor M. The HSP90 inhibitor onalespib potentiates 177Lu-DOTATATE therapy in neuroendocrine tumor cells. International Journal of Oncology. 2019, 55(6):1287-1295.
     
  5. Spiegelberg D, Mortensen A C, Lundsten S, Brown C J, Lane D P, Nestor M. The MDM2/MDMX-p53 antagonist PM2 radiosensitizes wild-type p53 tumors. Cancer Res., 2018, 78(17):5084-5093.
     
  6. Mortensen, AC, Spiegelberg D, Haylock A-K, Lundqvist H, Nestor M.  Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy. Int J Oncol. 2018, 52(6):1875-1885.
     
  7. Bondza S, Björkelund H, Nestor M, Andersson K, Buijs J. Novel Real-Time Proximity Assay for Characterizing Multiple Receptor Interactions on Living Cells. Anal Chem., 2017, 89(24):13212-13218.
     
  8. Haylock A-K, Nilvebrant J, Mortensen A, Velikyan I, Nestor M*, Falk R*. Generation and evaluation of antibody agents for molecular imaging of CD44v6-expressing cancers.  Oncotarget. 2017, 8(39):65152-65170. *shared senior authorship
     
  9. Spiegelberg D, Mortensen A, Selvaraju R, Eriksson O, Stenerlöw B, Nestor M. Evaluation of biomarkers for imaging and radio-immunotherapy in combination with HSP90 inhibition in squamous cell carcinomas.  Eur J Nucl Med Mol Imaging., 2016, 43(5):974-82.
     
  10. Sahlberg SH, Spiegelberg D, Glimelius B, Stenerlöw B, Nestor M. Evaluation of cancer stem cell markers CD133, CD44, CD24: association with AKT isoforms and radiation resistance in colon cancer cells. PLoS One. 2014, 9(4):e94621.